A rabies virus-vectored vaccine expressing two copies of the Marburg virus glycoprotein gene induced neutralizing antibodies against Marburg virus in humanized mice

References

• Geisbert TW, Daddario-DiCaprio KM, Geisbert JB, et al. Marburg virus Angola infection of rhesus macaques: pathogenesis and treatment with recombinant nematode anticoagulant protein c2. J Infect Dis. 2007 Nov 15;196(Suppl 2):S372–S381.
   PubMedGoogle Scholar
• Towner JS, Khristova ML, Sealy TK, et al. Marburgvirus genomics and association with a large hemorrhagic fever outbreak in Angola. J Virol. 2006 Jul;80(13):6497–6516.
   PubMed Web of Science ®Google Scholar
• Organization TWH. https://www.who.int/news/item/08-12-2017-uganda-ends-marburg-virus-disease-outbreak News release. 8 December 2017.
   Google Scholar
• Koundouno FR, Kafetzopoulou LE, Faye M, et al. Detection of Marburg virus disease in Guinea. N Engl J Med. 2022 Jun 30;386(26):2528–2530.
   PubMed Web of Science ®Google Scholar
• Schuh AJ, Amman BR, Sealy TK, et al. Antibody-mediated virus neutralization is not a universal mechanism of Marburg, Ebola, or Sosuga virus clearance in Egyptian rousette bats. J Infect Dis. 2019 May 5;219(11):1716–1721.
   PubMed Web of Science ®Google Scholar
• Schuh AJ, Amman BR, Sealy TK, et al. Egyptian rousette bats maintain long-term protective immunity against Marburg virus infection despite diminished antibody levels. Sci Rep. 2017 Aug 18;7(1):8763.
   PubMedGoogle Scholar
• Storm N, Van Vuren P J, Markotter W, et al. Antibody responses to Marburg virus in Egyptian Rousette bats and their role in protection against infection. Viruses. 2018 Feb 10;10(2):73.
   PubMed Web of Science ®Google Scholar
• Jones MEB, Amman BR, Sealy TK, et al. Clinical, histopathologic, and immunohistochemical characterization of experimental Marburg virus infection in a natural reservoir host, the Egyptian Rousette Bat (Rousettus aegyptiacus). Viruses. 2019 Mar 2;11(3):214.
   PubMed Web of Science ®Google Scholar
• Atherstone C, Diederich S, Pickering B, et al. Investigation of ebolavirus exposure in pigs presented for slaughter in Uganda. Transbound Emerg Dis. 2021 May;68(3):1521–1530.
   PubMed Web of Science ®Google Scholar
• Barrette RW, Metwally SA, Rowland JM, et al. Discovery of swine as a host for the Reston ebolavirus. Science. 2009 Jul 10;325(5937):204–206.
   PubMed Web of Science ®Google Scholar
• Kobinger GP, Leung A, Neufeld J, et al. Replication, pathogenicity, shedding, and transmission of Zaire ebolavirus in pigs. J Infect Dis. 2011 Jul 15;204(2):200–208.
   PubMed Web of Science ®Google Scholar
• Fusco ML, Hashiguchi T, Cassan R, et al. Protective mAbs and cross-reactive mAbs raised by immunization with engineered Marburg virus GPs. PLoS Pathog. 2015 Jun;11(6):e1005016.
   PubMed Web of Science ®Google Scholar
• Hashiguchi T, Fusco ML, Bornholdt ZA, et al. Structural basis for Marburg virus neutralization by a cross-reactive human antibody. Cell. 2015 Feb 26;160(5):904–912.
   PubMed Web of Science ®Google Scholar
• Lee JE, Fusco ML, Hessell AJ, et al. Structure of the ebola virus glycoprotein bound to an antibody from a human survivor. Nature. 2008 Jul 10;454(7201):177–182.
   PubMed Web of Science ®Google Scholar
• Reynard O, Borowiak M, Volchkova VA, et al. Ebolavirus glycoprotein GP masks both its own epitopes and the presence of cellular surface proteins. J Virol. 2009 Sep;83(18):9596–9601.
   PubMed Web of Science ®Google Scholar
• Francica JR, Varela-Rohena A, Medvec A, et al. Steric shielding of surface epitopes and impaired immune recognition induced by the ebola virus glycoprotein. PLoS Pathog. 2010 Sep 9;6(9):e1001098.
   PubMed Web of Science ®Google Scholar
• Aleksandrowicz P, Marzi A, Biedenkopf N, et al. Ebola virus enters host cells by macropinocytosis and clathrin-mediated endocytosis. J Infect Dis. 2011 Nov;204(Suppl 3):S957–S967.
   PubMedGoogle Scholar
• Manicassamy B, Wang J, Rumschlag E, et al. Characterization of Marburg virus glycoprotein in viral entry. Virology. 2007 Feb 5;358(1):79–88.
   PubMed Web of Science ®Google Scholar
• Nanbo A, Imai M, Watanabe S, et al. Ebolavirus is internalized into host cells via macropinocytosis in a viral glycoprotein-dependent manner. PLoS Pathog. 2010 Sep 23;6(9):e1001121.
   PubMed Web of Science ®Google Scholar
• Mulherkar N, Raaben M, de la Torre JC, et al. The ebola virus glycoprotein mediates entry via a non-classical dynamin-dependent macropinocytic pathway. Virology. 2011 Oct 25;419(2):72–83.
   PubMed Web of Science ®Google Scholar
• Saeed MF, Kolokoltsov AA, Albrecht T, et al. Cellular entry of ebola virus involves uptake by a macropinocytosis-like mechanism and subsequent trafficking through early and late endosomes. PLoS Pathog. 2010 Sep 16;6(9):e1001110.
   PubMed Web of Science ®Google Scholar
• Kuhn JH, Radoshitzky SR, Guth AC, et al. Conserved receptor-binding domains of lake Victoria Marburg virus and Zaire ebolavirus bind a common receptor. J Biol Chem. 2006 Jun 9;281(23):15951–8.
   PubMed Web of Science ®Google Scholar
• Flyak AI, Ilinykh PA, Murin CD, et al. Mechanism of human antibody-mediated neutralization of Marburg virus. Cell. 2015 Feb 26;160(5):893–903.
   PubMed Web of Science ®Google Scholar
• Bozhanova NG, Sangha AK, Sevy AM, et al. Discovery of Marburg virus neutralizing antibodies from virus-naive human antibody repertoires using large-scale structural predictions. Proc Natl Acad Sci U S A. 2020 Dec 8;117(49):31142–31148.
   PubMed Web of Science ®Google Scholar
• Froude JW, Pelat T, Miethe S, et al. Generation and characterization of protective antibodies to Marburg virus. MAbs. 2017 May/Jun;9(4):696–703.
   PubMed Web of Science ®Google Scholar
• Marzi A, Haddock E, Kajihara M, et al. Monoclonal antibody cocktail protects hamsters from lethal Marburg virus infection. J Infect Dis. 2018 Nov 22;218(suppl_5):S662–S665.
   PubMedGoogle Scholar
• Lee S, Yang JW, Jung SY, et al. Neuropsychological adverse drug reactions of Remdesivir: analysis using VigiBase, the WHO global database of individual case safety reports. Eur Rev Med Pharmacol Sci. 2021 Dec;25(23):7390–7397.
   PubMed Web of Science ®Google Scholar
• Falcao F, Viegas E, Carmo I, et al. A prospective, observational study to evaluate adverse drug reactions in patients with COVID-19 treated with remdesivir or hydroxychloroquine: a preliminary report. Eur J Hosp Pharm. 2021 Sep;28(5):248–253.
   PubMedGoogle Scholar
• Kim MS, Jung SY, Lee SW, et al. Hepatobiliary adverse drug reactions associated With remdesivir: The WHO international pharmacovigilance study. Clin Gastroenterol Hepatol. 2021 Sep;19(9):1970–1972.e3.
   PubMed Web of Science ®Google Scholar
• Zhang Z. Development of neutralizing monoclonal antibodies (mAbs) against Marburg virus. 2019.
   Google Scholar
• Sarwar UN, Costner P, Enama ME, et al. Safety and immunogenicity of DNA vaccines encoding ebolavirus and marburgvirus wild-type glycoproteins in a phase I clinical trial. J Infect Dis. 2015 Feb 15;211(4):549–557.
   PubMed Web of Science ®Google Scholar
• Jones SM, Feldmann H, Stroher U, et al. Live attenuated recombinant vaccine protects nonhuman primates against ebola and Marburg viruses. Nat Med. 2005 Jul;11(7):786–790.
   PubMed Web of Science ®Google Scholar
• Hevey M, Negley D, Pushko P, et al. Marburg virus vaccines based upon alphavirus replicons protect Guinea pigs and nonhuman primates. Virology. 1998 Nov 10;251(1):28–37.
   PubMed Web of Science ®Google Scholar
• Wang H, Jin H, Feng N, et al. Using rabies virus vaccine strain SRV9 as viral vector to express exogenous gene. Virus Genes. 2015 Apr;50(2):299–302.
   PubMed Web of Science ®Google Scholar
• Yu L, Yang X, Huang N, et al. Generation of fully human anti-GPC3 antibodies with high-affinity recognition of GPC3 positive tumors. Invest New Drugs. 2021 Jun;39(3):615–626.
   PubMed Web of Science ®Google Scholar
• Albertini AA, Ruigrok RW, Blondel D. Rabies virus transcription and replication. Adv Virus Res. 2011;79:1–22.
   PubMed Web of Science ®Google Scholar
• Liu XH, Yang YT, Sun ZJ, et al. A recombinant rabies virus encoding Two copies of the glycoprotein gene confers protection in dogs against a virulent challenge. PloS one 9.2 (2014):e87105.
   Google Scholar
• Cenna J, Tan GS, Papaneri AB, et al. Immune modulating effect by a phosphoprotein-deleted rabies virus vaccine vector expressing two copies of the rabies virus glycoprotein gene. Vaccine. 2008 Nov 25;26(50):6405–6414.
   PubMed Web of Science ®Google Scholar
• Xue XH, Zheng XX, Wang HL, et al. An inactivated recombinant rabies CVS-11 virus expressing two copies of the glycoprotein elicits a higher level of neutralizing antibodies and provides better protection in mice. Virus Genes. 2014 Jun;48(3):411–420.
   PubMed Web of Science ®Google Scholar
• Tao LH, Ge JY, Wang XJ, et al. Generation of a recombinant rabies flury LEP virus carrying an additional G gene creates an improved seed virus for inactivated vaccine production. Virol J. 2011 Sep 25;8.
   Web of Science ®Google Scholar
• Panasiuk M, Zimmer K, Czarnota A, et al. Chimeric virus-like particles presenting tumour-associated MUC1 epitope result in high titers of specific IgG antibodies in the presence of squalene oil-in-water adjuvant: towards safe cancer immunotherapy. J Nanobiotechnology. 2022 Mar 27;20(1):160.
   PubMed Web of Science ®Google Scholar
• Pihl AF, Feng S, Offersgaard A, et al. Inactivated whole hepatitis C virus vaccine employing a licensed adjuvant elicits cross-genotype neutralizing antibodies in mice. J Hepatol. 2022 May;76(5):1051–1061.
   PubMed Web of Science ®Google Scholar
• Ragotte RJ, Pulido D, Lias AM, et al. Heterotypic interactions drive antibody synergy against a malaria vaccine candidate. Nat Commun. 2022 Feb 17;13(1):933.
   PubMed Web of Science ®Google Scholar
• Moodie Z, Dintwe O, Sawant S, et al. Analysis of the HVTN 702 phase 2b-3 HIV-1 vaccine trial in South Africa assessing RV144 antibody and T-cell correlates of HIV-1 acquisition risk. J Infect Dis. 2022 Aug 24;226(2):246–257.
   PubMed Web of Science ®Google Scholar
• Yang HC X, Wu M, Zhenshan W, et al. Discovery and characterisation of SARS-CoV-2 reactive and neutralising antibodies from humanised CAMouse HG mice through rapid hybridoma screening and high-throughput single cell V(D)J sequencing. Front Immunol. 2022 Sep 23;13:992787.
   PubMed Web of Science ®Google Scholar
• Hevey M, Negley D, Staley A, et al. Determination of vaccine components required for protecting cynomolgus macaques against genotypically divergent isolates of Marburg virus. 20th Annual Meeting of the American Society for Virology; 2001.
   Google Scholar
• Bi J, Wang H, Pei H, et al. A novel and secure pseudovirus reporter system based assay for neutralizing and enhancing antibody assay against Marburg virus. Front Microbiol. 2022;13:927122.
   PubMed Web of Science ®Google Scholar
• Daddario-DiCaprio KM, Geisbert TW, Geisbert JB, et al. Cross-protection against Marburg virus strains by using a live, attenuated recombinant vaccine. J Virol. 2006 Oct;80(19):9659–9666.
   PubMed Web of Science ®Google Scholar
• Kuhn JH. Guide to the correct use of filoviral nomenclature. Curr Top Microbiol. 2017;411:447–460.
   PubMed Web of Science ®Google Scholar
• Wirblich C, Coleman CM, Kurup D, et al. One-Health: a safe, efficient, dual-Use vaccine for humans and animals against Middle East respiratory syndrome coronavirus and rabies virus. J Virol. 2017 Jan 3;91(2):e02040–16.
   PubMed Web of Science ®Google Scholar
• da Fontoura Budaszewski R, Hudacek A, Sawatsky B, et al. Inactivated recombinant rabies viruses displaying canine distemper virus glycoproteins induce protective immunity against both pathogens. J Virol. 2017 Mar 29;91(8):e02077–16.
   PubMed Web of Science ®Google Scholar
• Kurup D, Wirblich C, Feldmann H, et al. Rhabdovirus-based vaccine platforms against henipaviruses. J Virol. 2015 Jan;89(1):144–154.
   PubMed Web of Science ®Google Scholar
• Kurup D, Wirblich C, Ramage H, et al. Rabies virus-based COVID-19 vaccine CORAVAX induces high levels of neutralizing antibodies against SARS-CoV-2. NPJ Vaccines. 2020;5:98.
   PubMed Web of Science ®Google Scholar
• Luo J, Zhao J, Tian Q, et al. A recombinant rabies virus carrying GFP between N and P affects viral transcription in vitro. Virus Genes. 2016 Jun;52(3):379–387.
   PubMed Web of Science ®Google Scholar
• Stonier SW, Herbert AS, Kuehne AI, et al. Marburg virus survivor immune responses are Th1 skewed with limited neutralizing antibody responses. J Exp Med. 2017 Sep 4;214(9):2563–2572.
   PubMed Web of Science ®Google Scholar
• Natesan M, Jensen SM, Keasey SL, et al. Human survivors of disease outbreaks caused by ebola or Marburg virus exhibit cross-reactive and long-lived antibody responses. Clin Vaccine Immunol. 2016 Aug;23(8):717–724.
   PubMedGoogle Scholar
• Weiwei G, Xuexing Z, Chong W, et al. Marburg virus-like particles produced in insect cells induce neutralizing antibodies in rhesus macaques. J Med Virol. 2017 Dec;89(12):2069–2074.
   PubMed Web of Science ®Google Scholar
• Zhu W, Liu G, Cao W, et al. A cloned recombinant vesicular stomatitis virus-vectored Marburg vaccine, PHV01, protects Guinea pigs from lethal Marburg virus disease. Vaccines (Basel). 2022 Jun 23;10(7):1004.
   PubMed Web of Science ®Google Scholar
• Saito T, Maruyama J, Nagata N, et al. A surrogate animal model for screening of ebola and Marburg glycoprotein-targeting drugs using pseudotyped vesicular stomatitis viruses. Viruses. 2020 Aug 22;12(9):923.
   PubMed Web of Science ®Google Scholar
• Keshwara R, Hagen KR, Abreu-Mota T, et al. A recombinant rabies virus expressing the Marburg virus glycoprotein Is dependent upon antibody-mediated cellular cytotoxicity for protection against Marburg virus disease in a murine model. J Virol. 2019 Mar 5;93(6):e01865–18.
   PubMed Web of Science ®Google Scholar
• Ilinykh PA, Huang K, Santos RI, et al. Non-neutralizing antibodies from a Marburg infection survivor mediate protection by Fc-effector functions and by enhancing efficacy of other antibodies. Cell Host Microbe. 2020 Jun 10;27(6):976–991.e11.
   PubMed Web of Science ®Google Scholar